Take Solutions Ltd
Incorporated in 2000, TAKE Solutions Ltd is in the business of Life Sciences and Support Services[1]
- Market Cap ₹ 665 Cr.
- Current Price ₹ 44.4
- High / Low ₹ 49.9 / 6.51
- Stock P/E 3,324
- Book Value ₹ 1.73
- Dividend Yield 0.00 %
- ROCE 11.2 %
- ROE 644 %
- Face Value ₹ 1.00
Pros
- Company has reduced debt.
- Company is almost debt free.
Cons
- Stock is trading at 25.6 times its book value
- Company has low interest coverage ratio.
- Company has a low return on equity of -66.4% over last 3 years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 815.54 | 730.43 | 1,030.13 | 1,344.56 | 1,587.24 | 2,039.00 | 2,212.90 | 774.02 | 655.19 | 189.07 | 3.60 | -0.00 | 0.00 | |
| 668.26 | 581.00 | 816.83 | 1,082.14 | 1,280.69 | 1,655.34 | 2,043.98 | 847.05 | 647.92 | 207.95 | 24.08 | 7.43 | 2.24 | |
| Operating Profit | 147.28 | 149.43 | 213.30 | 262.42 | 306.55 | 383.66 | 168.92 | -73.03 | 7.27 | -18.88 | -20.48 | -7.43 | -2.24 |
| OPM % | 18.06% | 20.46% | 20.71% | 19.52% | 19.31% | 18.82% | 7.63% | -9.44% | 1.11% | -9.99% | -568.89% | ||
| 6.13 | 8.24 | 20.74 | 12.68 | 6.34 | 10.55 | 26.36 | -210.80 | -676.80 | -55.50 | -92.14 | 46.90 | 4.61 | |
| Interest | 13.77 | 12.69 | 14.79 | 22.62 | 20.76 | 25.01 | 41.27 | 37.31 | 29.34 | 7.45 | 2.27 | 1.96 | 0.59 |
| Depreciation | 76.88 | 59.61 | 74.29 | 87.45 | 104.15 | 153.51 | 166.93 | 115.38 | 79.81 | 16.84 | 0.72 | 0.05 | 0.01 |
| Profit before tax | 62.76 | 85.37 | 144.96 | 165.03 | 187.98 | 215.69 | -12.92 | -436.52 | -778.68 | -98.67 | -115.61 | 37.46 | 1.77 |
| Tax % | 1.59% | 6.37% | 13.86% | 11.44% | 14.96% | 17.29% | -15.25% | 3.11% | 0.46% | 1.70% | 3.47% | -0.00% | |
| 61.76 | 79.93 | 124.86 | 146.16 | 159.86 | 178.40 | -10.94 | -450.08 | -782.29 | -100.36 | -119.62 | 37.47 | 1.61 | |
| EPS in Rs | 4.74 | 5.71 | 9.78 | 10.74 | 10.85 | 11.99 | -0.84 | -30.56 | -52.88 | -6.78 | -8.09 | 2.53 | 0.12 |
| Dividend Payout % | 20.69% | 17.17% | 10.04% | 9.16% | 14.55% | 8.24% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | -100% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | -6% |
| 5 Years: | 38% |
| 3 Years: | 27% |
| TTM: | 101% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | -11% |
| 5 Years: | -5% |
| 3 Years: | 37% |
| 1 Year: | 333% |
| Return on Equity | |
|---|---|
| 10 Years: | -8% |
| 5 Years: | -52% |
| 3 Years: | -66% |
| Last Year: | 644% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 12.00 | 12.00 | 12.01 | 13.10 | 14.59 | 14.61 | 14.62 | 14.62 | 14.62 | 14.62 | 14.62 | 14.62 | 14.62 |
| Reserves | 458.05 | 512.42 | 619.29 | 897.84 | 1,313.70 | 1,503.62 | 1,560.73 | 1,110.07 | 166.42 | 93.98 | -23.50 | 5.91 | 11.01 |
| 206.51 | 208.79 | 336.39 | 237.27 | 322.64 | 473.92 | 553.24 | 514.18 | 58.51 | 46.37 | 37.09 | -0.00 | -0.00 | |
| 185.31 | 188.87 | 245.98 | 221.09 | 189.22 | 338.98 | 336.45 | 187.23 | 983.55 | 69.41 | 59.89 | 15.95 | 9.58 | |
| Total Liabilities | 861.87 | 922.08 | 1,213.67 | 1,369.30 | 1,840.15 | 2,331.13 | 2,465.04 | 1,826.10 | 1,223.10 | 224.38 | 88.10 | 36.48 | 35.21 |
| 383.99 | 358.60 | 542.79 | 554.25 | 588.68 | 1,091.34 | 1,233.52 | 933.75 | 101.13 | 73.20 | 30.25 | 0.01 | -0.00 | |
| CWIP | 2.05 | 16.52 | 2.67 | 20.61 | 42.45 | 41.25 | 0.83 | 0.21 | 3.39 | 10.72 | -0.00 | -0.00 | -0.00 |
| Investments | 50.15 | 6.05 | 21.22 | 9.50 | 59.19 | 10.23 | 17.50 | 7.44 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 |
| 425.68 | 540.91 | 646.99 | 784.94 | 1,149.83 | 1,188.31 | 1,213.19 | 884.70 | 1,118.58 | 140.46 | 57.85 | 36.47 | 35.21 | |
| Total Assets | 861.87 | 922.08 | 1,213.67 | 1,369.30 | 1,840.15 | 2,331.13 | 2,465.04 | 1,826.10 | 1,223.10 | 224.38 | 88.10 | 36.48 | 35.21 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 99.83 | 74.13 | 150.97 | 55.90 | 120.85 | 103.57 | 211.14 | 135.24 | 29.62 | 20.02 | 9.32 | -16.37 | |
| -90.89 | -13.62 | -292.22 | -129.74 | -178.94 | -473.86 | -233.32 | -57.45 | 14.92 | -2.57 | -7.46 | 22.13 | |
| -6.89 | -11.37 | 110.99 | 55.88 | 301.50 | 99.91 | 20.54 | -83.95 | -54.51 | -35.72 | -11.74 | -3.24 | |
| Net Cash Flow | 2.05 | 49.13 | -30.27 | -17.97 | 243.41 | -270.37 | -1.63 | -6.16 | -9.98 | -18.27 | -9.88 | 2.52 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 99.93 | 120.16 | 106.81 | 118.42 | 107.89 | 94.05 | 115.60 | 204.59 | 45.41 | 57.99 | 714.79 | |
| Inventory Days | ||||||||||||
| Days Payable | ||||||||||||
| Cash Conversion Cycle | 99.93 | 120.16 | 106.81 | 118.42 | 107.89 | 94.05 | 115.60 | 204.59 | 45.41 | 57.99 | 714.79 | |
| Working Capital Days | 32.18 | 41.70 | 18.87 | 89.62 | 84.88 | 67.12 | 80.46 | 140.22 | 27.89 | -42.22 | -5,559.15 | |
| ROCE % | 11.04% | 12.68% | 15.71% | 16.59% | 14.64% | 13.11% | 1.37% | -9.35% | -5.96% | -14.04% | -22.21% | 11.24% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Press Release / Media Release
21 Feb - 21 Feb 2026: Take Solutions integrates Anthropic's Claude to enhance AI-driven preventive healthcare platforms and Unified AI Marketplace.
- Intimation Of Cut-Off Date For The Purpose Of The Extra Ordinary General Meeting Of The Company 18 Feb
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
17 Feb - Newspaper Advertisement of the Unaudited Financial Results for the quarter and nine months ended December 31, 2025.
-
Announcement under Regulation 30 (LODR)-Press Release / Media Release
17 Feb - 17 Feb 2026: TAKE to build Unified AI Platform to transform USD 370bn Indian healthcare ecosystem.
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
16 Feb - Newspaper Advertisement of Notice of Extra Ordinary General Meeting
Annual reports
-
Financial Year 2025
from bse
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
Concalls
-
Aug 2021TranscriptPPT
-
Jun 2021TranscriptPPT
-
Feb 2021TranscriptPPT
-
Dec 2020TranscriptPPT
-
Sep 2020TranscriptPPT
-
Oct 2019TranscriptPPT
-
Aug 2019TranscriptPPT
-
May 2019TranscriptPPT
-
Mar 2019TranscriptPPT
-
Feb 2019TranscriptPPT
-
Feb 2019TranscriptPPT
-
Aug 2018TranscriptPPT
-
May 2018TranscriptPPT
-
Feb 2018TranscriptPPT
-
Nov 2017TranscriptPPT
-
Nov 2017TranscriptPPT
-
Aug 2017TranscriptPPT
-
May 2017TranscriptPPT
-
Jan 2017TranscriptPPT
-
Dec 2016TranscriptPPT
-
Oct 2016TranscriptPPT
-
Feb 2016TranscriptAI SummaryPPT
Business Overview:[1]
Singapore-based TAKE Solutions Pte Limited holds a 52.90% stake in TSL, serving as the holding company. TSL specializes in Life Sciences and Supply Chain Management, providing comprehensive services in clinical development and specific offerings in supply chain. The company is involved in clinical trials, generics support, including bio-availability & bioequivalent studies, regulatory filing, and pharmacovigilance.